[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642917":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":52,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":26,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Indiana University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Netarsudil (Rhopressa)","ACTIVE_COMPARATOR","Participants will receive netarsudil ophthalmic solution administered as one drop in the study eye once daily in the evening for approximately 14 days.",[13],"Drug: Netarsudil Ophthalmic Solution (Rhopressa)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo (Artificial Tears)","PLACEBO_COMPARATOR","Participants will receive artificial tears administered as one drop in the study eye once daily in the evening for approximately 14 days.",[19],"Other: Artificial Tears (AT)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Netarsudil Ophthalmic Solution (Rhopressa)","Netarsudil ophthalmic solution is an FDA-approved Rho kinase inhibitor indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, it will be administered once daily in the evening for approximately 14 days.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Artificial Tears (AT)","Artificial tears will be used as a placebo control and administered once daily in the evening for approximately 14 days. These drops are not expected to lower intraocular pressure or alter trabecular meshwork structure.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Brett J King, OD","CONTACT","(812) 855-1344","kingbrj@iu.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":26},"Indiana Universtiy School of Optometry","RECRUITING","Bloomington","Indiana","47405","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-86.52639,39.16533,{"lat":50,"lon":49},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Brett King","Principal Investigator",[57],{"name":58,"class":59},"Alcon Research","INDUSTRY","100642917","phase-4-imaging-the-effects-of-netarsudil-rhopressa-on-the-trabecular-meshwork-in-glaucoma-and-ocular-hypertension-100642917",false,"NCT07588152","Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension","Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of ocular hypertension or open-angle glaucoma\n* Eye examination within the past year\n* For glaucoma subjects: structural (optic nerve and\u002For retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma\n* Best-corrected visual acuity of 20\u002F100 or better\n* Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)\n* Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)\n\nExclusion Criteria:\n\n* Known intolerance to netarsudil ophthalmic solution\n* Corneal scarring or active corneal disease that would interfere with imaging\n* Inability to tolerate gonioscopy procedures\n* Females of childbearing potential who are not using effective contraception or are not sterile\n* Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion","ALL","18 Years",{"count":70,"type":71},50,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.",[77,78],"Glaucoma","Ocular Hypertension","2026-06-09",{"date":81,"type":82},"2026-06-11","ACTUAL",{"date":84,"type":82},"2026-06-05",{"date":86,"type":71},"2028-06",{"name":5,"class":6},1]